Michelle Dawson posts

Post published on Twitter/X on 10 May 2021 02:30

Back to posts Previous post Next post
Twitter/X Clinical trial clinicaltrials.gov Extract quoted in the post External link integrated into the post Autism terms
Open original post

1 integrated reply by Michelle Dawson

10 May 2021 02:33

Note: among this trial's exclusion criteria for autistics was "Significant risk for suicidal behavior, in the opinion of the investigator"

View reply on Twitter/X

Information about the link integrated into the post

Clinical trial

Hoffmann-La Roche (2018). A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension. ClinicalTrials.gov. Hoffmann-La Roche.

More information

Structured cited links

1 cited resource

Clinical trial Fetched Post clinicaltrials.gov

Hoffmann-La Roche (2018). A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension. ClinicalTrials.gov. Hoffmann-La Roche.

Publication date
8 Aug 2018
Identifier
NCT03504917
Authors
Hoffmann-La Roche
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Hoffmann-La Roche
Metadata source
clinicaltrials.gov

Abstract

This study will evaluate the efficacy, safety, and pharmacokinetics of 10 mg of oral administration balovaptan once a day (QD) compared with matching placebo in adults (18 years and older) with autism spectrum disorder (ASD).

Open source Link to cited source